SUPPLEMENTAL **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

		ous sign (+) illside this box		rsons are required to rest	Patent a condite a collection of information unle	Approve Ise through the Approv	PTO SB 08A (10-96) gn 10 21 99 9MB 0651-0031 PATMENT OF COMMERCE 120 0 900		
	Subst to	ute for form 1449A PTO				Complete if Known	6CP 4 H 2007		
					Application Number	10/038,517	DEL 10 2002		
SUPPLEMENTAI INFORMATION DISCLO STATEMENT BY APPL	١,	SUPPLEM	EN.	ΓΑL	Filing Date	1/3/02			
	OSURE	First Named Inventor	Yu						
					Group Art Unit	1621			
	STA	ALEMENT BA	AP	PLICANI	Examiner Name	To be assigned			
	Shee	1	01	1	Attorney Docket Number	LEX-0293-USA			

			U.S. PATENT DOCUMEN	TS			
Cite	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Pages, Columns, Lines.		
No.	Number	Kind Code [:] (<i>if known</i>)	of Cited Document	of cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear		
					_		
	Cite -	Cite	No Number Kind Code	Cite No Number U.S Patent Document Name of Patentee or Applicant of Cited Document	Cite Name of Patentee or Applicant of cited Document of cited Document		

				FORE	IGN PATENT DOCUMENTS			
Examine	Cite	Foreign Patent Document			Name of Patentee or	Date of Publication	Pages, Columns, Lines,	
r Initials*	No.1	Office	Number ⁴	Kind Code ⁵ (<i>if known</i>)	Applicant of Cited Document	of cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Т6
We	СК	wo	0125409	A1	Millenium Pharmacueticals	04/12/01	pg-05-90	
								┢

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
MC	CL	Database EBI 'Online' NIH-MGC, STRAUSBERG, Robert, "601854965F1 NIH, MGC 57 Homo sapiens cDNA clone IMAC 4074544 5', mRNA sequence," 11/16/00, database accession no. BF246347, XP002220407, abstract.	Œ:
NC	СМ	THIRSTRUP, et al., "Cloning and expression in insect cells of two pancreatic lipases and a procolipase from Myocastor coypus," European Journal of Biochemistry, Vol. 227, No. 1-2, 1995, pgs. 186-193, XP001119728, ISSN: 0014-2956.	
We	Z /	THIRSTRUP, et al., "Evidence for a pancreatic lipase subfamily with new kinetic properties," Biochemistry, Vol. 33, No. 10, 1994, pgs. 2748-2756, XP001119733, ISSN: 0006-2960.	
R	CO	Database NCBI 'Online', SMITH, D.R., "Human Genome Sequencing Center," 10/06/99, database accession no. AC011328, XP002220408.	
R		SVENDSEN, Allan, "Lipase protein engineering," Biochimica et Biophysica Acta, Amsterdam, NL, Vol. 1543, No. 2, 2000, pgs. 223-238, XP002200729, ISSN: 0006-3002.	
We	ca	LOWE, et al., "Cloning and Characterization of Human Pancreatic Lipase cDNA," Journal of Biological Chemistry, Vol. 264, No. 33, 11/25/89, pgs. 20042-20048, XP000081766, ISSN: 0021-9258.	
ve	_·	International Search Report, International Application No. PCT/US02/00223, 01/03/02 (Attorney Docket No. LEX-0293-PCT)	

Examiner Signature	Walred	1/30/04	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents. Washington, DC 20231.

EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box + 3

Sheet

of

PTO S8 08A (10-96)
pproved for use through 10/31/99 OMB 0651-0031
Patent are emark Office, U.S. DEPARTMENT OF COMMERCE

LEX-0293-USA

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid QMB control number

Substitute for form 1449A PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

Application Number 10/038,517

Filing Date 01/03/02

First Named Inventor Yu

Group Art Unit 1621

Examiner Name To be assigned

Attorney Docket Number

	AFR	S LUUZ .		U.S. PATENT DOCUMENTS	3	
xaminer nitials*	No. 3 /	U.S. Pate 11 C	Nocument Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Schlick Houres Appear
w	-AA	4,215,051	<u> </u>	Schroeder et al	07/29/80	549/250
1	AB	4,376,110		David et al 47.6472.3	03/08/83	436/5/3
1	AC	4,594,595		Struckman	06/10/86	342/710
	AD	4,631,211		Houghten	12/23/86	428/35.5
1	AE	4,689,405		Frank et al	08/25/87	536/25-3
1	AF	4,713.326		Dattagupta et al	12/15/87	435/6
 	AG	4,873,191		Wagner et al	10/10/89	800/25
1	АН	4,946,778		Ladner et al	08/07/90	435/69-6
	Al	5,252,743		Barrett et al	10/12/93	548/303.7
	AJ	5,272,057	1	Smulson et al.	12/21/93	435/6
1	AK	5,424,186		Fodor et al	06/13/95	435/6 m
1	AL	5,445,934		Fodor et al	08/29/95	43岁6 皇
\top	AM	5,459,127		Felgner et al	10/17/95	514/70 = 111
	AN	5,556,752		Lockhart et al	09/17/96	435/6 7 20
1	AO	5,700,637		Southern	12/23/97	48/6 m ~ m
+	AP	5,744,305		Fodor et al	04/28/98	435/6 = ~
+-	AQ	5.830.721		Stemmer et al	11/03/98	435/4998 3
	AR	5,837,458		Minshull et al	11/17/98	435/12 20 111
\neg	AS	5,858,755		Lowe	01/12/99	435/1988
 	AT	5,869,336		Meyer et al.	02/09/99	435/348
	AU	5,877,397		Lonberg et al	03/02/99	800/18
	AV	5,948,767		Scheule et al.	09/07/99	514/44
17	AW	6,075,181		Kucherlapati et al	06/13/00	800/25
7	AX	6,110,490		Thierry	08/29/00	424/450
Ne	AY	6,150,584		Kucherlapati et al.	11/21/00	80t/18
	<u> </u>					
· E	<u> </u>					

	Examiner Signature	Wated	1/30/04	Date Considered
--	-----------------------	-------	---------	--------------------

^{*}EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents. Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449B-PT0	0		Complete if Known			
INECOPRETION		OCUPE	Application Number	10/038,517		
IIYFUNIVIATION	TATEMENT BY APPLICANT APR 1 9 7002 (use as many sheets as necessary)	LUSUNE	Filing Date	01/03/02		
STATEMENT BY APPLICAN	PLICANI	First Named Inventor	Yu			
APR 1 9 2002	NFORMATION DISCLOSURE STATEMENT BY APPLICANT APR 19 0002 (use as many sheets as necessary)		Group Art Unit	1621		
(use as many she	els as necess	ary)	Examiner Name	To be assigned		
Sheek 2	of	3	Attorney Docket Number	LEX-0293-USA		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T².
Me	ΑZ	Bird et al, 1988, "Single-Chain Antigen-Binding Proteins", Science 242:423-426.	
bel	ВА	Bitter et al, 1987, "Expression and Secretion Vectors for Yeast", Methods in Enzymology 153:516-544.	
LOR	BB	Colbere-Garapin et al, 1981, "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells", J. Mol. Biol. 150:1-14.	
we	вс	Gautier et al, 1987, "α-DNA IV:α-anomeric and β-anomeric tetrathymidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physiochemical properties and poly (rA) binding", Nucleic Acids Research 15(16):6625-6641.	
Ne	ВD	Gordon, 1989, "Transgenic Animals", International Review of Cytology, 115:171-229.	
190	BE	Greenspan et al, 1993, "Idiotypes: structure and immunogenicity", FASEB Journal 7:437-444.	
we	BF	Gu et al, 1994, "Deletion of a DNA Polymerase β Gene Segment in T Cells Using Cell Type-Specific Gene Targeting", Science 265:103-106.	
Ne	BG	Huse et al. 1989, "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda", Science 246:1275-1281.	
Ne	BH 	Huston et al. 1988, "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxim ingle-chain Fv analogue produced in Escherichia coli", Proc. Natl. Acad. Sci. USA 85:5879-5883.	
NR	ВІ	Induce et al, 1987, "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and R Nase FEBS Letters 215(2):327-330.	d
he	BJ 	Inoue et al, 1987, "Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides Nucleic Acids Research 15(15):6131-6149.	1
we	BK	Inouye & Inouye, 1985, "Up-promoter mutations in the Ipp gene of Escherichia coli", Nucleic Acids Research 1993;31	ď
We	BL	Janknecht et al, 1991, "Rapid and efficient purification of native histidine-tagged protein expressed by recombent vaccinia virus", PNAS 88:8972-8976.	q
Kp	ВМ	Kohler & Milstein, 1975, "Continuous cultures of fused cells secreting antibody of predefined specificity", Nature 256:495-497.	
W	BN	Lakso et al, 1992, "Targeted oncogene activation by site-specific recombination in transgenic mice", Proc. Natl. Acad. Sci. USA 89:6232-6236.	
We	во	Lavitrano et al, 1989, "Sperm Cells as Vectors for Introducing Foreign DNA into Eggs: Genetic Transformation of Mice", Cell 57:717-723.	
Ne	BP -	Lo, 1983, "Transformation by fontophoretic Microinjection of DNA: Multiple Integrations without Tandem Insertions", Mol. (Cell. Biology 3(10):1803-1814.	
Ne	BQ	Logan et al, 1984, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection", Proc. Natl. Acad. Sci. USA 81:3655-3659.	
10	BR	Lowy et al. 1980, "Isolation of Transforming DNA: Cloning the Hamster aprt Gene", Cell 22:817-823.	

Examiner Signature	Weshed	1/30/04	Date Considered	

EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Unique citation designation number. * See attached Kinds of U.S. Patent Documents. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Palents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid CMB control number

Substitute for form 1449B.PTO	Complete if Known			
INFORMATION DISCLOSURE	Application Number	10/038,517		
	Filing Date	01/03/02		
STATEMENT BY APPLICANT	First Named Inventor	Yu		
APR 1 9 2002 (2)	Group Art Unit	1621		
(use as many sheets as necessary)	Examiner Name	To be assigned		
Sheet 3 4 of 3	Attorney Docket Number	LEX-0293-USA		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_
	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	BS ·	Morrison et al, 1984, "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains", Proc. Natl. Acad. Sci. USA 81:6851-6855.	\prod
	ВТ	Mulligan & Berg, 1981, "Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase", Proc. Natl. Acad. Sci. USA 78(4):2072-2076.	
	BU	Neuberger et al. 1984, "Recombinant antibodies possessing novel effector functions", Nature 312:604-608.	
M	в۷	Nisonoff, 1991, "Idiotypes: Concepts and Applications", J. of Immunology 147:2429-2438.	
Q	BW -	O'Hare et al, 1981, "Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase", Proc. Natl. Acad. Sci. USA 78(3):1527-1531.	
هر	₽X	Ruther et al, 1983, "Easy identification of cDNA clones", EMBO Journal 2(10):1791-1794.	
R	BY	Santerre et al, 1984, "Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells", Gene 30:147-156.	
	BZ	Sarin et al, 1988, Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates", Proc. Natl. Acad. Sci. USA 85:7448-7451.	
R	CA	Smith et al, 1983, "Molecular Engineering of the Autographa californica Nuclear Polyhedrosis Virus Genome: Deletion Mutations within the Polyhedrin Gene", J. Virol. 46(2):584-593.	
re	CB	Stein et al. 1988, "Physiochemical properties of phosphorothioate oligodeoxynucleotides", Nucleic Acids Research 16(8):3209-3221.	
re	CC	Szybalska & Szybalski, 1962, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", Proc. Natl. Acad. Sci. USA 48:2026-2034.	
R	CD	Takeda et al, 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", Nature 314:452-454.	
Pl	CE	Thompson et al. 1989, "Germ Line Transmission and Expression of a Corrected HPRT Gene Produced by Gene Targetin Embryonic Stem Cells", Cell 56:313-321.	
R	CF	Van Der Putten et al, 1985, "Efficient insertion of genes into the mouse germ line via retroviral vectors", Proc. Natl. Acad. Sci. USA 82:6148-6152.	
re	CG /	Van Heeke et al, 1989, "Expression of Human Asparagine Synthetase in Escherichia coli", J. Biol. Chemetry 264(10):5503-5509.	
\mathcal{L}	СН	Ward et al, 1989, "Binding activities of a repertoire of single immunoglobulin variable domains secreted bom Emberi (nia coli", Nature 341:544-546.	į
رو آ	CI .	Wigler et al, 1977, "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells", Cell 1 223-242	
بو	CJ	Wigler et al. 1980. "Transformation of mammalian cells with an amplifiable dominant-acting gene", Pro Natl. Asad. St. USA 77(6):3567-3570.	
		98 D	

Examiner	ACT act	1/20/04	Date	
Signature	A sheet	1/30/01	Considered	

^{*}EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.